Kornimate/medical-research-clean huggingface dataset:
storage symptom after laser prostatectomy

Conditions: Prostatic Hyperplasia

Summary: recent literature indicated that postoperative storage symptoms after photoselective vaporization of the prostate (pvp) or holmium laser enucleation of the prostate (holep) were often reported and generally more common than after transurethral prostatectomy (turp). however, almost all literature focused on postoperative urgency or dysuria immediately after pvp or holep. thus, there has been a scarcity of data on serial changes of storage symptoms in the postoperative period after pvp or holep and data on predicting factors that influence improvement in storage symptoms postoperatively. the aim of this study was to compare serial changes of postoperative storage symptoms between pvp and holep, and to identify the predictors that influence improvement of storage symptoms postoperatively.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of prostatic hyperplasia * underwent photoselective vaporization of the prostate or holmium laser enucleation of the prostate * 12-months follow-up data were available exclusion criteria: * previous diagnosis of urethral stricture, prostate carcinoma, and neurogenic bladder disease
endobronchial intubation of double-lumen tube: conventional method vs fiberoptic bronchoscope guide method

Conditions: Intubation, Intratracheal; Postoperative Complications; Sore Throat; Hoarseness; Soft Tissue Injuries; Thoracic Surgery

Summary: double lumen tube (dlt) needs to be intubated to isolate ventilations of left and right lungs for thoracic surgery. post-operative sore throat and hoarseness are more frequent with dlt intubation than with single one. which is may because dlt is relatively thicker, harder, sideway curved and therefore more likely to damage the vocal cord or trachea during intubation, and advanced deeper to the carina and main bronchus level. in the conventional method of intubation, dlt is rotated 90 degrees and advanced blindly to the main bronchus level after dlt is intubated through vocal cord using the direct laryngoscopy. after the blind advancement, the sufficient tube position needs to be gained and confirmed with the fiberoptic bronchoscope. in the bronchoscope guide method, after dlt is intubated through vocal cord using the direct laryngoscopy, the pathway into the targeted main bronchus is secured using the fiberoptic bronchoscope which is passed through a bronchial lumen of dlt. and then dlt can be advanced through the guide of the bronchoscope. in this study, we intend to compare post-operative sore throat, hoarseness and airway injury between the two methods. we hypothesize that the bronchoscope guide method can reduce the post-operative complications and airway injury because surrounding tissues of the airway can be less irritated by dlt intubation in the guide method than in a conventional. for a constant guide effect, we use fiberoptic bronchoscopes with same outer diameter (4.1 mm) which can pass through a bronchial lumen of 37 and 39 fr lt. dlt and cannot pass through 35 fr or smaller lt. dlts. \ * male: ≥160 cm, 39 french; \< 160 cm, 37 french * female: ≥160 cm, 37 french; \< 160 cm, contraindication


Eligibility criteria:
inclusion criteria: * asa (american society of anesthesiologists) class i - iii * elective thoracic surgery * left-sided dlt intubation for one-lung ventilation exclusion criteria: * female, height \< 160 cm * pre-existing sore throat, hoarseness or airway injury * duration of surgery \> 6 h * upper respiratory tract infection * cervical spine diseases * presence of tracheostomy * pharyngeal neoplasm or abscess which can induce mechanical airway obstruction * mallampati score 4 * obesity (bmi ≥ 35 kg/m2) * obstructive sleep apnea (osa) * craniofacial anomaly * cormack grade 3b or 4 * history or high risk of difficult intubation / difficult mask ventilation * patients whom the direct laryngoscopy cannot be used for, because of weak teeth or small mouth opening * patients who refuse to participate in the study or from whom receive informed consent cannot be received.
post isometric relaxation and mulligan bent leg raise on hamstring tightness in high school students

Conditions: Hamstring Injury; Hamstring Tendon Injury

Summary: this project was a randomized clinical trial conducted comparative study of post isometric relaxation and mulligan bent leg raise on hamstring tightness in high school students

non probability convenient sampling was done. patients following eligibility criteria from high schools located in vicinity of jhang district were considered. sample size was calculated with epitool calculator. 28 participants were randomly allocated in two groups equally via convenient sampling method. baseline assessment was done initially. group a was given post isometric relaxation and group b was given mulligan bent leg raise duration of research was almost 6 months. all 28 involved subjects were given 12 treatment sessions over a six-week period, which consisted of 02 treatment sessions per week . then tightness of hamstrings was assessed by aket, slr and ftf test. the baseline outcome measures consisted of pain assessment using numeric rating scale (nprs), knee joint goniometry in active knee extension test (aket) and straight leg raise (slr), modified finger to floor test (ftf) to assess the flexibility of hamstring muscles. . all participants were provided written informed consent prior to commencement of the procedures. data was analyzed by using spss version 23.

Eligibility criteria:
inclusion criteria: asymptomatic individuals of both gender, aged 13 to 18 years were evaluated for unilateral or bilateral hamstring tightness. those who were unable to reach more than 160 degree of knee extension with hip held at 90 degree of flexion, as measured with the thigh held at 90 degrees of hip flexion), unable to complete slr and meet the criteria of finger to floor test were included. exclusion criteria: individuals were excluded who presented with previous injury of lower limb or pain duration of one year. also any deformities related to spine, hip and knees or any neurological disorder or with history of lower limb fracture or surgery were also excluded.subjects with hamstring tightness associated with muscle soreness or with inflammatory condition that could affect motion were also exluded from the study
prodromes of menstrual staphylococcal toxic shock

Conditions: Toxic Shock Syndrome Staphylococcal

Summary: menstrual staphylococcal toxic shock is a rare but severe disease, requiring intensive care in over 80% of cases. menstrual staphylococcal toxic shock develops during the peri-menstrual period, in healthy young women colonized by a vaginal strain of staphylococcus aureus secreting the toxic shock syndrome toxin 1 (tsst-1) and not immune to it, in a favorable environment, i.e. wearing intravaginal menstrual protection (tampon, menstrual cup). the rarity of the syndrome, its polymorphous clinical presentation and the absence of a totally specific biological examination make menstrual staphylococcal toxic shock a difficult pathology to diagnose. the reference clinical criteria correspond to the advanced picture of multivisceral failure, making it possible to classify cases a posteriori, but contribute to diagnostic delay and lack sensitivity. patient accounts suggest the presence of symptoms in the days preceding the development of toxic shock, and also during previous menstrual cycles. the identification of prodromal symptoms could enable earlier management of menstrual staphylococcal toxic shock by removal of intra-vaginal sanitary protection, the main risk factor, before the disease becomes permanently established and requires intensive care.


Eligibility criteria:
inclusion criteria : +case inclusion criteria: * women between 13 and 30 years old inclusive * clinical diagnosis of staphylococcal toxic shock syndrome: "confirmed" or "probable" according to center disease control (cdc) criteria: the 5 cdc clinical criteria for menstrual staphylococcal toxic shock are: * a fever above 39°c, * arterial hypotension, * generalized scarlatiniform erythroderma * intense peeling of the palms or soles of the feet 7 to 14 days later, * and systemic manifestations (at least three): * digestive: vomiting, diarrhea * muscular: myalgia, increase in serum creatine phosphokinase * hyperemia of the vaginal, oropharyngeal and conjunctival mucous membranes * renal: hyperuricemia, hypercreatininemia, leukocyturia without urinary infection, * hepatic: increase in transaminases * hematological: thrombocytopenia (\< 100,000 platelets/mm3) * neurological: apart from episodes of fever or hypotension such as disorientation or altered consciousness. in the presence of 4 criteria, the case is considered probable and 5 criteria as confirmed case. * detection of s. aureus strain carrying toxic shock syndrome toxin-1 (tsst1) on vaginal samples. * onset of symptoms ≤ 72 hours before the start of menstruation and ≥ 72 hours after the end of menstruation. * use during the last 3 cycles of vaginal protection: tampon or menstrual cup. +control inclusion criteria: * women between 13 and 30 years old inclusive * presence of menstruation * use of intimate periodic protection, tampon or menstrual cup, during the last 3 periods * no history of toxic menstrual shock exclusion criteria: * non-menstruating women * women protected by law * women (or relatives) who oppose the study

Keywords: menstrual toxic shock staphylococcus aureus prodromes
expansion of abbreviations and acronyms for patients

Conditions: Heart Failure

Summary: this is a prospective, two-arm, parallel, individually randomized controlled trial to estimate the effect of expansion on patient comprehension (primary outcome) of abbreviations and acronyms in their health records. english-speaking adult patients with diagnosed heart failure who receive primary care at three urban hospitals in new york city will be considered. the investigators hypothesize that expansion will significantly increase patient comprehension of abbreviations and acronyms in the health record.

importance: in 2020, an estimated 100 million americans accessed their own health records online. that number likely increased beginning april 2021, when u.s. federal rules implemented the 21st century cures act requiring electronic health information to be made freely accessible. medical abbreviations and acronyms may limit patient understanding of health records. automated expansion is one potential solution, however, the magnitude of its effect on patient comprehension has not been estimated. objective: to estimate the effect of expansion on patient comprehension of abbreviations and acronyms in their health records. design: prospective, two-arm, parallel, individually randomized controlled trial. participants: patients who receive primary care at one of three urban hospitals. a purposive sample representative on age, gender, and race will be enrolled between february 2020 and august 2021. to isolate the main effect, the investigators will include only english-speaking adult patients with diagnosed heart failure. intervention: participants will be randomized to receive clinical text with abbreviations (control group, n=30) or with expansions (intervention group, n=30). the abbreviations and expansions included "hrs" (hours), "md" (medical doctor), "bp" (blood pressure), "ed" (emergency department), "yo" (year old), "pt" (patient), "hf" (heart failure), "hx" (history), "htn" (hypertension), "mi" (myocardial infarction).

Eligibility criteria:
inclusion criteria: * adult (21 years or older) * confirmed diagnosis of heart failure * able to read and speak english * willing and able to provide informed consent * receives primary care from participating provider exclusion criteria: * healthcare professional (md, do, rn, etc.) * no telephone number or email address * severe cognitive impairment or clinical diagnosis of dementia * major psychiatric illness, including active psychosis * other illness that would preclude participation

Keywords: abbreviations acronyms personal health records patient portals consumer health informatics patient access to records
a novel act-based video game

Conditions: Depression; Anxiety; Stress, Emotional; Quality of Life; Psychological Flexibility; Social Connecedness

Summary: a feasibility study to explore whether an acceptance and commitment therapy (act) can reduce mental health outcomes (stress, anxiety, depression) and increase psychological flexibility.


Eligibility criteria:
inclusion criteria: * adults reporting some existing form of anxiety, depression or ongoing stress. * need ability to read and write english. * need internet access to play the videogame. exclusion criteria: * those who are under 18
exploratory study of art-123 for the prevention of cancer treatment related symptoms in patients with postoperative stage ii / iii colon cancer

Conditions: Postoperative Stage II/III Colon Cancer

Summary: the purpose of this study is to evaluate the efficacy and safety of art-123 for the prevention of cancer treatment related symptoms in patients with postoperative stage ii / iii colon cancer.


Eligibility criteria:
main inclusion criteria: * diagnosed with stage ii / iii colon cancer * deemed to have undergone curative a (cur a) surgery * planning to undergo postoperative adjuvant chemotherapy main exclusion criteria: * have a history of hypersensitivity to any of the ingredients in thrombomodulin alfa (recombinant) * have any treatment history of systemic chemotherapy (including any drug in the clinical trial stage) or radiotherapy * with active double cancer
preoperative dextrose infusion and postoperative nausea and vomiting

Conditions: Effect of Dextrose on Postoperative Nausea and Vomiting

Summary: this research aims to investigate the efficacy of preoperative intravenous infusion of dextrose 5% during fasting in lowering the incidence and severity of post-operative nausea and vomiting related to laparoscopic gynaecologic procedures

a history of ponv risk factors will be recorded. after consenting, patients will be assigned using a computerized randomization function to ringer solution (group r) or 5% dextrose (group d) or control group (group c). group d will receive 1 ml/kg/h 5% dextrose infusion, applied preoperatively during fasting until induction of anesthesia. group r will receive 1 ml/kg/h ringer infusion, applied preoperatively during fasting until induction of anesthesia. group c will receive no fluids. the anesthesia providers, surgeons, perioperative nurses, postanesthesia care unit (pacu) nurses and investigators will be blinded to group assignment throughout. as for pre-medication, all patients will receive iv midazolam (0.02 mg/kg). anesthesia will be induced with propofol (1.5-2 mg/kg), fentanyl (1-2 μg/kg) and atracurium(o.5mg/kg) to facilitate endotracheal intubation. the lungs will be mechanically ventilated and anesthesia will be maintained with isoflurane in o2/air. intraoperative iv maintenance fluid will be standardized at 3 ml/kg/h with additional iv crystalloid given as needed at the discretion of the anesthesia provider if arterial blood pressure decreased \&gt;20% from baseline. for postoperative pain relief, paracetamol 1 g will be given i.v. during surgery in all patients and continued orally after operation (1g every 6 h). in addition, all patients will be ambulated within 6 h after completion of surgery. standardized antiemetic and analgesic rescue medications will be available. patients will receive no rescue antiemetic medication when the vrs score is 0 to 2; 1 dose of rescue medication when the vrs score is 3 to 6; and ≥2 doses for nausea score of 7 to 10, to reduce the nausea score to 0 to 2.

Eligibility criteria:
inclusion criteria: * adult female patients scheduled for elective laparoscopic gynecological/hysteroscopic procedures will be considered for inclusion * asa physical status i and ll. exclusion criteria: * patients with a previous history of ponv. * patients with motion sickness, coagulopathy, diabetes mellitus, or severe hypertension * patients with cardiac, renal or hepatic dysfunction. * patients receiving an antiemetic agent within 24 h before surgery or cases where complications occurs during the surgery * patients who have abnormal blood glucose on the night before surgery * patients who are unable to understand and use the verbal rating scale (vrs);growth developmental, and motor-mental retardation.

Keywords: dextrose infusion postoperative nausea and vomiting gynecological laparoscope and hysteroscope
topical morphine for stomatitis-related pain induced by chemotherapy

Conditions: Pain; Mucositis

Summary: stomatitis/oral mucositis is a common side effect to chemotherapy. stomatitis is often associated with painful ulcers in the mouth. the study hypothesis is that morphine administrated as a mouthwash can relieve stomatitis-related pain by a local analgesic effect. the purpose of this study is to test the analgesic effect of a morphine mouthwash versus morphine injections or placebo (no active drug) in children/adolescents with stomatitis related to chemotherapy. besides the investigational drugs (morphine mouthwash and morphine injections) the children/adolescents receive a standardized analgesic treatment for stomatitis-related pain.


Eligibility criteria:
inclusion criteria: * children and adolescents at the juliane marie center at copenhagen university hospital (rigshospitalet, denmark) or at the university hospital in lund (sweden) * receiving chemotherapy in relation to a cancer disease * pain score of minimum 3 (vas-scale) at rest for mouth pain in combination with stomatitis of minimum grade 1 (who-scale) or a pain score of minimum 5 (vas-scale) at activity for mouth pain in combination with stomatitis of minimum grade 1 (who-scale) * negative pregnancy test, when relevant (judged by physician) * patients and/or parents understand and speak danish (denmark) / swedish (sweden) * signed informed consent exclusion criteria: * allergic to the investigational medical product * alcohol or drug abuse

Keywords: morphine mouthwash mucositis pain cancer child adolescent
oral supplementation of glutamine on gastric cancer patients after gastrectomy

Conditions: Gastric Cancer; Immunonutrition; Gastrostomy

Summary: glutamine has the potentials of immunomodulation and adjustment of protein metabolism. the primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. the secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.

this will be a double-blind, randomized, and placebo-controlled study. at least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. each group will have at least 40 patients. the ct scan will be evaluated before surgery and on postoperative day (pod) 90. moreover, the patient will wear the smart watch to record daily walking steps. laboratory data will be check before gastrectomy and on pod 90.

Eligibility criteria:
inclusion criteria: * adult gastric cancer receiving gastrectomy exclusion criteria: * hepatic insufficiency * renal insufficiency * can not tolerate oral or enteral feeding 7 days after gastrectomy * can not receive computed tomograph * can not waer the wearable devices

Keywords: gastric cancer gastrectomy sarcopenia
comparison of a new formulation of insulin glargine with lantus® both in combination with oral antihyperglycemic drug(s) in japanese patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: primary objective: to compare the efficacy of a new formulation of insulin glargine and lantus in terms of change of hba1c from baseline to endpoint (scheduled at month 6 \[week 26\]) in japanese patients with type 2 diabetes mellitus. secondary objectives: to compare a new formulation of insulin glargine and lantus in terms of change in fasting plasma glucose (fpg), preinjection plasma glucose, 8-point self-measured plasma glucose (smpg) profile. to compare a new formulation of insulin glargine and lantus in terms of occurrence of hypoglycemia

the duration of study will consist of: * up to 2-week screening period; * 6-month open-label comparative efficacy and safety treatment period; * 6-month open-label comparative safety extension period; * 4-week post-treatment safety follow-up period

Eligibility criteria:
inclusion criteria : o patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of screening visit treated with basal insulin in combination with oral antihyperglycemic drugs (oads) for at least 6 months before screening visit; exclusion criteria: * age \< 18 years at screening visit; * bmi(body mass index) ≥ 35 kg/m2 at screening visit; * hba1c \ 10% (national glycohemoglobin standardization program \[ngsp\] value) at screening visit; * diabetes other than type 2 diabetes mellitus; * patients on self-monitoring of blood glucose less than 6 months before screening visit; * patients using pre-mix insulins, insulin detemir at 2 times or more a day, or glp 1 receptor agonists in the last 3 months before screening visit; * patients using mealtime insulin (rapid-acting insulin analogue and short-acting insulin) for more than 10 days in the last 3 months before screening visit; * use of insulin pump in the last 6 months before screening visit; * initiation of new glucose-lowering medications and/or weight loss drugs in the last 3 months before screening visit; * severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit; * unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic retinopathy or macular edema likely to require treatment (eg, laser, surgical treatment or injectable drugs) during the study period. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.